Payment overview · 2025
General Payments
$960.94
54 reported records · 15 companies
Healthcare provider profile · identity verified
Veronica Michelle Patterson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COMMERCE, GA · NPI 1962408997
Verified facts
What the public records show
CMS Open Payments records show Veronica Michelle Patterson, M.D. received $960.94 in general payments during 2025 across 54 reported records.
Novo Nordisk Inc accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Shingrix, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $291.88 | 30.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.29 | 16.3% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.60 | 11.7% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.13 | 10.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.67 | 5.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.77 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.42 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.49 | 3.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.59 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.60 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.76 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.58 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.99 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.46 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.71 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $960.94 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $207.62 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $121.89 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.60 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.25 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.25 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.26 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.04 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.28 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.42 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 185 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 184 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 217 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 140 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 82 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 25 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
85 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
184 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
124 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
140 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
217 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
140 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 769 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 749 | 123 |
| Gabapentin | Gabapentin | 732 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 687 | 104 |
| Potassium Chloride | Potassium Chloride | 504 | 45 |
| Omeprazole | Omeprazole | 463 | 72 |
| Furosemide | Furosemide | 454 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 119 |
| Alprazolam | Alprazolam | 380 | 50 |
| Lisinopril | Lisinopril | 348 | 71 |
| Metformin Hcl | Metformin Hcl | 325 | 72 |
| Sertraline Hcl | Sertraline Hcl | 313 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 304 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 37 |
| Eliquis | Apixaban | 278 | 25 |
| Losartan Potassium | Losartan Potassium | 277 | 54 |
| Allopurinol | Allopurinol | 268 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 35 |
| Tramadol Hcl | Tramadol Hcl | 249 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 44 |
| Ozempic | Semaglutide | 217 | 43 |
| Carvedilol | Carvedilol | 197 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 19 |
| Mirtazapine | Mirtazapine | 193 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 190 | 22 |
| Farxiga | Dapagliflozin Propanediol | 188 | 33 |
| Famotidine | Famotidine | 186 | 47 |
| Jardiance | Empagliflozin | 185 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 184 | 16 |
| Mounjaro | Tirzepatide | 184 | 32 |
| Donepezil Hcl | Donepezil Hcl | 181 | 11 |
| Trazodone Hcl | Trazodone Hcl | 175 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 31 |
| Buspirone Hcl | Buspirone Hcl | 165 | 16 |
| Levetiracetam | Levetiracetam | 159 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 158 | suppressed |
| Meloxicam | Meloxicam | 158 | 29 |
| Lorazepam | Lorazepam | 151 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 23 |
| Rexulti | Brexpiprazole | 140 | suppressed |
| Clonazepam | Clonazepam | 139 | 23 |
| Memantine Hcl | Memantine Hcl | 138 | 13 |
| Atenolol | Atenolol | 131 | 21 |
| Olanzapine | Olanzapine | 131 | suppressed |
| Valsartan | Valsartan | 129 | 27 |
| Xarelto | Rivaroxaban | 127 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 124 | 31 |
| Trulicity | Dulaglutide | 124 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 122 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 19 |
| Alendronate Sodium | Alendronate Sodium | 111 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 105 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 16 |
| Promethazine Hcl | Promethazine Hcl | 100 | 13 |
| Azelastine Hcl | Azelastine Hcl | 99 | 38 |
| Ezetimibe | Ezetimibe | 96 | 29 |
| Januvia | Sitagliptin Phosphate | 96 | 13 |
| Cefdinir | Cefdinir | 92 | 74 |
| Clonidine Hcl | Clonidine Hcl | 88 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 21 |
| Metformin Hcl Er | Metformin Hcl | 88 | 19 |
| Sucralfate | Sucralfate | 86 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 16 |
| Rybelsus | Semaglutide | 82 | 17 |
| Azithromycin | Azithromycin | 81 | 56 |
| Novolog Flexpen | Insulin Aspart | 81 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 78 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 76 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 15 |
| Meclizine Hcl | Meclizine Hcl | 75 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 18 |
| Pregabalin | Pregabalin | 72 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | suppressed |
| Simvastatin | Simvastatin | 68 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 17 |
| Myrbetriq | Mirabegron | 66 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 13 |
| Febuxostat | Febuxostat | 62 | suppressed |
| Glimepiride | Glimepiride | 62 | 17 |
| Memantine Hcl Er | Memantine Hcl | 62 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 13 |
| Bupropion Xl | Bupropion Hcl | 61 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 15 |
| Linzess | Linaclotide | 60 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 11 |
| Cilostazol | Cilostazol | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Lamivudine | Lamivudine | 52 | suppressed |
| Methylprednisolone | Methylprednisolone | 52 | 43 |
| Glipizide | Glipizide | 51 | 12 |
| Telmisartan | Telmisartan | 51 | 12 |
| Nitroglycerin | Nitroglycerin | 50 | 24 |
| Verapamil Er | Verapamil Hcl | 50 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 48 | suppressed |
| Diazepam | Diazepam | 47 | 16 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 16 |
| Ondansetron Odt | Ondansetron | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Cephalexin | Cephalexin | 41 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 28 |
| Estradiol | Estradiol | 39 | 15 |
| Fluconazole | Fluconazole | 39 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Vascepa | Icosapent Ethyl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Prednisone | Prednisone | 34 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 11 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Finasteride | Finasteride | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 25 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 12 |
| Fentanyl | Fentanyl | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Nystatin | Nystatin | 27 | 22 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 20 |
| Temazepam | Temazepam | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Cholestyramine Light | Cholestyramine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Progesterone | Progesterone, Micronized | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 19 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Novolog | Insulin Aspart | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Tivicay | Dolutegravir Sodium | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Mupirocin | Mupirocin | 15 | 14 |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Terconazole | Terconazole | 15 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $960.94 · 54 records | Novo Nordisk Inc | Auvelity, CAPLYTA, Cologuard Collection Kit, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error